A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of MabThera plus high dose methotrexate plus
high dose cytarabine in patients with central nervous system non-Hodgkin's lymphoma. Eligible
patients will receive a treatment regimen consisting of MabThera (750mg/m2 iv) plus
methotrexate (8g/m2 iv) given at intervals up to week 22, plus cytarabine (2g/m2 iv) at week
11 and week 22. The anticipated time on study treatment is 3-12 months, and the target sample
size is <100 individuals.